You are here

Prices & Quotes - UK Markets - Oxford Biomedica (OXB)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Down 1,004.00p
Change Today:
-10.00p
Market Cap:
827.50m
Sector:
Pharmaceuticals & Biotechnology

Oxford Biomedica strikes three-year deal with Boehringer Ingelheim

By Josh White

Date: Tuesday 06 Apr 2021

LONDON (ShareCast) - (Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new three-year development and supply agreement with Boehringer Ingelheim, it announced on Tuesday, for the manufacture and supply of various types of viral vectors.
The FTSE 250 firm said that under the agreement, it would manufacture GMP batches for Boehringer Ingelheim to support the development of viral vectors.

It said the agreement also allowed for the group to manufacture and supply viral vector products in the future.

"This development and supply agreement with Boehringer Ingelheim demonstrates the good progress made in our partnership with Boehringer Ingelheim, which started in 2018," said chief executive officer John Dawson.

"We are proud to be supporting another global pharmaceutical company in the development and manufacturing of their viral vector programs."

Dawson said the company now had a portfolio of partnerships across the development of CAR-Ts, TCR-Ts and in vivo gene therapeutics, using lentiviral vectors.

"We are proud to partner with Boehringer Ingelheim, a business with proven excellence in complex manufacturing projects, as well as expertise in developing innovative medicines for patients with serious unmet medical needs."

At 0819 BST, shares in Oxford Biomedica were up 1.89% at 970p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OXB Market Data

Currency UK Pounds
Price 1,004.00p
Change Today -10.00p
52 Week High 1,110.00p
52 Week Low 701.00p
Volume 52,960
Shares Issued 82.42m
Market Cap 827.50m
Beta 0.01

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. half market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
Price Trend
market
  1. full market star
  2. full market star
  3. full market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. empty sector
  4. empty sector
  5. empty sector
Income
Not Available
Growth
market
  1. full market star
  2. full market star
  3. full market star
  4. half market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. empty sector
  5. empty sector
Price Chg 6m
market
  1. full market star
  2. full market star
  3. half market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector
P/E
Not Available
PEG
market
  1. full market star
  2. full market star
  3. full market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. empty sector
Dividend Yield
Not Available
EPS Growth
Not Available
Operating Margin
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector

What The Brokers Say

Strong Buy 3
Buy 0
Neutral 1
Sell 0
Strong Sell 1
Total 5
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for 14-May-2021

Time Volume / Share Price
16:35 17,819 @ 1,004.00p
16:29 551 @ 1,007.49p
16:28 493 @ 1,008.97p
16:27 37 @ 1,007.48p
16:27 6 @ 1,010.00p

OXB Key Personnel

CEO John Dawson
CFO Stuart Paynter